Hyperphosphatemia - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 77 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hyperphosphatemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hyperphosphatemia - Pipeline Review, H2 2014', provides an overview of the Hyperphosphatemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia - Overview 8
Pipeline Products for Hyperphosphatemia - Comparative Analysis 9
Hyperphosphatemia - Therapeutics under Development by Companies 10
Hyperphosphatemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia - Products under Development by Companies 15
Hyperphosphatemia - Companies Involved in Therapeutics Development 16
Astellas Pharma Inc. 16
AstraZeneca PLC 17
Medice Arzneimittel Putter GmbH & Co. KG 18
Mitsubishi Tanabe Pharma Corporation 19
OPKO Health, Inc. 20
Panion & Bf Biotech Inc 21
Sanofi 22
Spectrum Pharmaceuticals, Inc. 23
Toray Industries, Inc. 24
Vifor Pharma AG 25
Hyperphosphatemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
ASP-3325 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
colestilan chloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Fe-SAMMS - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
fermagate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ferric citrate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
JPH-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
niacinamide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PT-20 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RDX-002 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SPI-014 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
sucroferric oxyhydroxide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tenapanor hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TRK-390 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VS-501 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VS-505 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Hyperphosphatemia - Recent Pipeline Updates 56
Hyperphosphatemia - Dormant Projects 68
Hyperphosphatemia - Discontinued Products 69
Hyperphosphatemia - Product Development Milestones 70
Featured News & Press Releases 70
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 70
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 70
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 71
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 71
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 72
Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 73
Aug 27, 2014: Velphoro receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis 73
Aug 27, 2014: Velphoro receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis 74
Jul 24, 2014: Zerenex (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology 74
Jun 27, 2014: Velphoro recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products under Development for Hyperphosphatemia, H2 2014 8
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Hyperphosphatemia - Pipeline by Astellas Pharma Inc., H2 2014 16
Hyperphosphatemia - Pipeline by AstraZeneca PLC, H2 2014 17
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H2 2014 18
Hyperphosphatemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 19
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H2 2014 20
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H2 2014 21
Hyperphosphatemia - Pipeline by Sanofi, H2 2014 22
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 23
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H2 2014 24
Hyperphosphatemia - Pipeline by Vifor Pharma AG, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H2 2014 56
Hyperphosphatemia - Dormant Projects, H2 2014 68
Hyperphosphatemia - Discontinued Products, H2 2014 69